The case for & against
Bull & Bear analysis
Bearish
Integer Holdings Corporation (NYSE: ITGR) is a leading provider in the medical device sector, specializing in cardiovascular, neuromodulation, and orthopedic devices. The company has established a strong foothold in high-growth markets, particularly within the electrophysiology domain, while maintaining a robust operational foundation for innovation and scalability. Integer is adapting to changing market dynamics through strategic investments and acquisitions, highlighting its commitment to enhancing patient outcomes and shareholder value.
Bull says
- ↑Order backlog of ~$700–800M provides clear sales visibility through year-end
- ↑Strategic investments in electrophysiology target a high-growth segment
- ↑Free cash flow projected at $100–120M in 2026 supports liquidity
- ↑Completed $50M share repurchase underlines disciplined capital return
- ↑Leadership transition emphasizes strategy refinement and cost management
- ↑High earnings yield and disciplined cost controls offset margin pressures
Bear says
- ↓2026 sales outlook down 1–3% amid disappointing new product adoption
- ↓Adjusted operating margin contracted to 13.9%, signaling profitability pressure
- ↓Net debt of $1.264B drives leverage to 3.2× adjusted EBITDA
- ↓Organic sales growth only 1.3%, highlighting weak top-line momentum
- ↓Analyst consensus is Hold, reflecting cautious institutional sentiment
- ↓Profitability factors remain weak and leverage risks are elevated
Investment themes with ITGR
Medical Devices↑ +0.12%
Devices and instruments for medical treatment
ISRG · ABT · SYK
Demographics: Elderly Care↓ -0.26%
Services and products for aging population
UCB.BR · JNJ · AZN
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-02-2026neutral
Transcript signals
Bull points
- Our adjusted effective tax rate was 19% versus 17.4% in the first quarter of 2025. We continue to expect our full year tax rate to be in the range of 16 to 18%.
- adjusted weighted average shares outstanding in the quarter decreased by 2%, reflecting our share repurchase activity.
- We now expect our adjusted EBITDA to be in the range of $375 to $399 million, down 1 to 7% versus the prior year.
Bear points
- First quarter sales totaled $440 million, up 0.5% on a reported basis, and up 1.3% on an organic basis.
- Adjusted operating income declined 14% versus last year, and our adjusted operating margin contracted 230 basis points to 13.9%, both in line with our February outlook.
- we now expect reported sales to be in the range of $1,805,000,000 to $1,835,000,000. On a year-over-year basis, we now expect sales to be down 1% to 3% on a reported basis and flat to down 1% on an organic basis.
Read full transcript analysis ›